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Abstract 
Background: Osteoarthritis (OA) is characterized by progressive loss of cartilage in joints, and is a major cause of pain 
and disability, and imposes significant health care expense. New therapies are being developed to treat the sympto-
matic effect of OA, one of which is intra-articular injection of viscosupplementations of different forms of hyaluronic 
acid (HA). The current study evaluates the chemical exchange saturation transfer (CEST) effect from two popular 
viscosupplementations [Hylan gf-20 (Synvisc) and hyaluronan (Orthovisc)] by targeting the exchangeable hydroxyl 
protons present on these molecules (ViscoCEST).
Methods: ViscoCEST imaging from two viscosupplementations (Synvisc and Orthovisc) was performed on a 7T 
Siemens whole body MRI scanner. ViscoCEST images were collected with different combination of saturation pulse 
power and saturation duration. Z spectra were acquired at B1rms of 3.6 μT and 1 s saturation duration by varying the 
frequency from −4 to +4 ppm in step size of 0.1 ppm. Field inhomogeneity (B0) and radiofrequency (B1) maps were 
also acquired to correct ViscoCEST contrast map for any inhomogeneity.
Results: Both viscosupplementations showed broad CEST effect (ViscoCEST), which peaked ~0.8 ppm from down 
field of water resonance. Orthovisc showed 20 % higher ViscoCEST contrast than Synvisc suggestive of more HA 
component in Orthovisc. Increased ViscoCEST contrast was observed from both viscosupplementations with increase 
in B1rms and saturation pulse duration.
Conclusion: ViscoCEST has a potential to image the spatial distribution of viscosupplements in vivo in patients’ intra-
articular space as well as temporal variation in their spatial distribution.
© 2016 Haris et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Osteoarthritis (OA), a major cause of pain and disability, 
is characterized by the progressive loss of cartilage tis-
sue, increased synovial fluid, inflammation and decreased 
viscoelasticity of the synovial fluid within the affected 
joint. Hyaluronic acid (HA) is the major source of non-
sulfated glycosaminoglycan (GAG) in the cartilage extra-
cellular matrix and help in maintaining the intra-articular 
lubrication and optimizing the viscoelasticity of synovial 
fluid. In OA, the concentration and molecular weight of 
HA decreases in affected joints and makes it more sus-
ceptible to the mechanical stress [1, 2].
New therapies are being developed to treat the symp-
tomatic effect of OA, one of which is intra-articular 
injection of viscosupplementations of different forms of 
HA [3, 4]. In recent years, the concept of viscosupple-
mentation has gained widespread acceptance as a new 
treatment for the management of knee OA. Both pre-
clinical and clinical studies have showed the potential of 
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progression [4, 5]. In an animal model of knee OA the 
intra-articular injected HA reduced the cartilage degen-
eration and inhibited the expression of pro-inflammatory 
markers including interleukin-1 beta and metalloprotein-
ase-3 [6–9]. Studies have demonstrated that the intra-
articular injected HA helps with joint repair through its 
effect on chondrocyte growth and metabolism as well 
as with synthesis of endogenous HA, proteoglycan, and 
collagen [10]. In humans, it is observed that the intra-
articular injected HA may improve cartilage morphol-
ogy and reduce synovial fluid inflammation and cartilage 
degradation over a period of 6 months to 1 year [11, 12]. 
Despite various subjective studies demonstrating alle-
viation of patients’ pain after intra-articular injection of 
viscosupplementation, there is still controversy in the use 
and efficacy of viscosupplementations [13, 14]. Thus, a 
noninvasive, quantitative imaging technique that is spe-
cific to viscosupplementation is needed to probe their 
fate in intra-articular space following injection, and their 
impact on the overall GAG concentration in cartilage.
Imaging methods that have been used to assess the OA 
disease progression include plain X-ray and conventional 
magnetic resonance imaging (MRI) scans. Plain X-ray 
provides an indirect measure of loss or thinning of car-
tilage by measuring the joint space narrowing (JSN) [15]. 
On the other hand, MRI provides high resolution images 
of cartilage morphology and integrity. Changes in the 
cartilage thickness measurement on conventional MRI 
may be helpful to observe the therapeutic efficacy over a 
long period of potential treatment.
However, there are contradictory reports of HA treat-
ment efficacy based on the plain-X ray and conventional 
MRI measurement of cartilage. Subjects either received 
intra-articular injection of HA or saline showed no differ-
ence for the JSN measurement [16]. Similarly, MRI study in 
patients with HA or saline injection found no difference for 
cartilage defect scoring between the two groups even after 
8 weeks of treatment [17]. In another study, decreased car-
tilage T2 relaxation time has been shown after intra-artic-
ular injection of hyaluronic acid in a rat model of OA [18].
Although both techniques (plain X-rays and conven-
tional MRI) can reflect the structural changes in carti-
lage, but do not have enough sensitivity to detect early 
biochemical changes in cartilage components. However, 
to date there is no in vivo study demonstrating the poten-
tial of HA viscosupplements molecules in influencing the 
molecular changes in articular cartilage. Recently, chemi-
cal exchange saturation transfer (CEST) imaging tech-
nique has been used to image the GAG concentration 
of cartilage by targeting the exchangeable hydroxyl pro-
tons (–OH) on GAG (GagCEST) [19, 20]. In GagCEST, 
application of frequency selective radiofrequency pulses 
saturates the –OH protons on GAG and exchange of this 
saturated magnetization with those of bulk water protons 
results in the decrease of the bulk water magnetization. 
This decrease in bulk water magnetization can be used 
to quantify and map the GAG concentration. Feasibility 
of mapping GAG in the human knee cartilage through 
GagCEST has been evaluated both on 3T and 7T human 
scanner [20]. Since hyaluronan, a non-sulfated GAG in 
viscosupplementations also possess –OH protons, we 
hypothesize that it would be possible to observe CEST 
effect from them (ViscoCEST), and it may be possible 
to probe the spatial distribution of viscosupplements in 
knee cartilage in  vivo after intra-articular injection of 
viscosupplementaions.
In the current study, we evaluated the ViscoCEST 
effect from two popular viscosupplementations [Hylan 
gf-20 (Synvisc) and Hyaluronan (Orthovisc)] by exploit-
ing the exchangeable –OH protons present on these 
molecules. We also assessed the saturation pulse ampli-
tude and saturation pulse duration effect on ViscoCEST 
contrast of these viscosupplemantations. Finally, we 
compared the optimal parameters for GagCEST from 




The CEST technique is based on chemical exchange 
between a solvent pool (typically water) and a solute 
pool, a small metabolite or proteins. The solute pool has 
exchangeable protons with a distinct chemical shift from 
the bulk water protons. Application of the frequency 
selective radiofrequency irradiation on exchangeable 
protons of the solute pool leads to the saturation of solute 
spins, with zero net magnetization, and exchange of these 
with bulk water protons results in the decrease of bulk 
water signal. This saturation transfer magnetization can 
be imaged to detect the CEST effect from a solute, which 
provides an indirect measure of solute concentration. In 
order for the CEST effect to be efficiently observed, the 
slow to intermediate exchange condition (chemical shift 
of exchangeable spins, ∆ω > k) must be fulfilled.
In biological tissues, magnetization transfer (MT) 
effects from the bound water protons and the direct 
water saturation interfere with the CEST analysis. To 
account for these effects, two CEST images are acquired: 
one with by applying saturation pulse at the resonance 
frequency of the exchangeable spins and other at the 
equal frequency on the other side of the bulk water peak. 
Signal difference in these two images can alleviate the 
MT effect. Normalizing this difference signal with the 
signal obtained without saturation provides the CEST 
effect from the exchangeable protons of solute as given in 
the following equation.
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where Msat (±∆ω) are the magnetizations obtained with 
saturation at ‘+’ or ‘–’ ∆ω offset of the water protons 
resonance  and M0 is the magnetization obtained with-
out saturation. In biological tissues due to short transfer 
relaxation times of water, the application of saturation 
pulse can lead to substantial direct water saturation 
which can attenuates the CEST effect. This can be mini-
mized to some extent by using Msat (–∆ω) [21] instead of 
M0 to normalize the signal differences. The other factors 
which can substantially affect the CEST contrast are B0 
and B1 field variations. As the CEST contrast is obtained 
by subtracting the two images (−∆ω and ∆ω), any asym-
metry generated due to the local B0 field inhomogeneity 
will contaminate the actual CEST contrast. On the other 
hand the B1 inhomogeneity affects both the CEST con-
trast as well as the direct water saturation. The accurate 
quantification and correction of B0 and B1 inhomogenei-
ties are important to obtain reliable CEST contrast [22].
MR imaging
For this study, we used two brands of viscosupplemen-
tations i.e. Hylan gf-20 (Synvisc, Genzyme Biosurgery) 
and Hyaluronan (Orthovisc, DePuy Mitek) that are being 
widely used for treating OA patients. Both clinical grade 
samples were obtained in closed plastic tubes from the 
manufacturer. Orthovisc has a lower molecular weight 
than Synvisc but contains a higher concentration of hya-
luronic acid per injection than Synvisc. Both products 
have been already shown their treatment efficacy in alle-
viating pain associated with OA [23, 24] and are consid-
ered high molecular weight hyaluronic acid compounds.
The ViscoCEST imaging was performed on a 7T 
Siemens whole body MRI scanner (Siemens Medi-
cal Systems, Malvern, PA, USA). The experiments were 
performed at 37  °C using a custom designed Styrofoam 
chamber to maintain the temperature at 37 ± 1  °C dur-
ing the course of experiment. A frequency selective 
saturation pulse followed by a segmented RF spoiled 
gradient echo (GRE) readout sequence was used. A 
saturation pulse train consisting of 5–30 Hanning win-
dowed rectangular pulses of 100 ms duration each with 
a 200 μs delay between them was employed. The satura-
tion pulse excitation bandwidth was 5 Hz for a 1 s pulse 
with 1 % bandwidth of 20 Hz. The total repetition time 
of the sequence was adjusted to stay within specific 
absorption rate (SAR) limits. The sequence parameters 
were: slice thickness  =  10  mm, GRE flip angle  =  10o, 
GRE readout TR  =  5.6  ms, TE  =  2.7  ms, field of 
view = 100 × 100 mm2, matrix size = 192 × 192, and one 




ViscoCEST images were collected with different combi-
nation of saturation pulse power (B1rms = 0.7 μT, 1.4 μT, 
2.2 μT, 2.9 μT, 3.6 μT, 4.4 μT) and saturation duration. Z 
spectra were collected at B1rms 3.6 μT and 1 s saturation 
duration by varying the frequency from −4 to +4  ppm 
in step size of 0.1 ppm. The field inhomogeneity (B0) and 
radiofrequency (B1) maps were also gathered using the 
method described in details elsewhere [20].
For reproducibility of GagCEST result at 7T as shown 
previously [20], we also performed GagCEST imaging from 
knee cartilage of a normal human healthy volunteer. The 
Institutional Review Board Committee of the University of 
Pennsylvania approved the study protocols. With informed 
consent the volunteer underwent GagCEST imaging using 
the optimal CEST parameters: B1rms of 2.2 μT and 0.5  s 
saturation duration [20]. The other imaging parameters 
were-slice thickness  =  5  mm, flip angle  =  10°, readout 
TR = 5.6 ms, TE = 2.7 ms, field of view = 140 × 140 mm2, 
matrix size = 192 × 192 with delay of 8 s.
Image processing
The acquired CEST weighted images were first corrected 
for B0 and then used to compute the CEST contrast map 
using equation [1]. The CEST contrast map was further 
corrected for any B1 inhomogeneity and overlaid on ana-
tomical proton weighted image as described in detail by 
Singh et al. [20].
Results and discussion
Z spectra and Z spectral asymmetry curves of ViscoCEST 
are shown in Fig. 1. Z spectral asymmetry curves clearly 
showed the broad CEST peak centered ~0.8 ppm in both 
viscosupplementations (Fig.  1). For the same saturation 
parameters Orthovisc depicted higher ViscoCEST con-
trast compared to Synvisc as clearly observed from Z 
spectra asymmetry curves (Fig. 1). The ViscoCEST map 
at B1rms of 3.6 μT and 1  s saturation duration (Fig.  2) 
showed ~20 % higher ViscoCEST contrast from Orthov-
isc than Synvisc. The higher ViscoCEST contrast from 
Orthovisc might be due to its higher concentration of 
HA and therefore possesses more exchangeable –OH 
protons than Synvisc. 
Figure 3 shows B1rms and saturation duration depend-
ent ViscoCEST effect from these molecules. Both visco-
supplementations showed increased CEST contrast with 
increase in B1rms and saturation pulse duration. Graphs 
clearly showed that the optimal B1rms is 3.6 μT to observe 
the optimal ViscoCEST contrast from both viscosupple-
mentations. The saturation parameters can be further 
optimized, however, in the current study, it was con-
strained by the SAR limit of the scanner.
Currently, there is no technique to monitor and track 
the fate of the injected viscosupplementations in knee 
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joints of OA patients over time as well as their effect 
on knee cartilage GAG concentration. Different in  vivo 
MR studies have been reported to monitor the changes 
in GAG content in human knee cartilage. The GdDTPA 
enhanced method [25–27] and spin lock T1rho tech-
niques [28, 29] have been widely used to monitor the 
GAG changes in knee cartilage. The beneficial effect of 
intra-articular injected HA in increasing the total carti-
lage volume in knee osteoarthritis patients who under-
went high tibial osteotomy has been shown recently [30]. 
However, none of these methods can provide changes in 
the GAG concentration following injection of viscosup-
plementations. Recently, the GagCEST method has been 
developed to image the GAG concentration in cartilage. 
The GagCEST technique has been evaluated to map the 
GAG changes in knee cartilage both at 3T and 7T [20]. 
Anup et al. have showed that using GagCEST technique 
the knee GAG content can be imaged at high resolu-
tion on 7T, while no appreciable GagCEST contrast was 
observed from 3T [20]. More direct water saturation 
and fast exchange regime of the GAG –OH protons at 
3T compared to 7T could be the possible reasons for the 
negligible GagCEST contrast at 3T.
Singh et al. have showed that the optimal parameter to 
observe the GagCEST contrast at 7T is 2.2 μT B1rms and 
500  ms saturation pulse duration [20]. We reproduced 
the GagCEST map of a human knee cartilage at 7T using 
the optimal GagCEST parameters as described by Singh 
et al. showed similar GagCEST contrast (Fig. 4). Increas-
ing or decreasing saturation pulse power or saturation 
pulse duration leads to decrease in GagCEST contrast 
from the knee cartilage. While, the current study showed 
that 3.6 μT Hz is the optimal B1rms and saturation dura-
tion of >1.5 s is required to observe optimal ViscoCEST 
contrast from both viscosupplementations. It should 
be noted that with optimal parameters for endogenous 
GagCEST (2.2 μT B1rms and 500 ms saturation) both the 
viscosupplementations provide a ViscoCEST contrast of 
only  ~30  % of the maximum value. On the other hand, 
with the optimal parameters for viscosupplmentation, the 
endogenous GagCEST from cartilage is negligibly small. 
Therefore, using GagCEST, it may be possible to monitor 
the GAG content changes in cartilage following viscosup-
plemntation injection, and at the same time ViscoCEST 
potentially enables probing of temporal and spatial dis-
tribution of viscosupplementations in the intraarticular 
space.
Conclusions
Our initial results demonstrate that both Orthovisc than 
Synvisc viscosupplements exhibit –OH group exchange 
Fig. 1 Z-spectra and Z-spectra assymetry curves show the gagCEST effect from Orthovisc and Synvisc, which peaks ~0.8 ppm. Higher gagCEST 
contrast is depicted from Orthovisc than Synvisc
Fig. 2 Shows the gagCEST contrast maps from Orthovisc and Synvisc 
overlaid on anatomical proton image. The gagCEST map is showing 
higher contrast from Orthovisc
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mediated CEST effect and they can be measured using 
ViscoCEST. In addition, ViscoCEST has potential to 
assess the spatial and temporal variation of these visco-
supplementats in vivo. Further studies in these lines are 
currently in progress in our laboratory.
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Fig. 3 Saturation pulse and saturation duration dependence ViscoCEST contrast. a and b Graphs show the saturation pulse amplitude (B1rms) and 
saturation duration dependent ViscoCEST contrast from Synvisc and Orthovisc. Increase in ViscoCEST contrast is observed with increased saturation 
power and saturation pulse duration. c Graph is showing B1rms dependent ViscoCEST contrast from Orthovisc and Synvisc for the saturation dura-
tion of 2 s
Fig. 4 The GagCEST map from a healthy human knee cartilage is 
showing distribution of glycosaminoglycan on knee cartilage
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